Improvement of Libman-Sacks Endocarditis With Combined Hydroxychloroquine-Vitamin K Antagonist Therapy in a Primary Antiphospholipid Syndrome Patient

Loukman Omarjee; Vincent Jaquinandi; Audrey Camarzana; Frederic Rouleau; Tin-Hinan Mezdad; Thierry Le Tourneau; Guillaume Mahe; Cristina Belizna

doi:10.1253/circj.CJ-17-1131

Improvement of Libman-Sacks Endocarditis With Combined Hydroxychloroquine-Vitamin K Antagonist Therapy in a Primary Antiphospholipid Syndrome Patient

Circ J. 2018 Aug 24;82(9):2380-2382. doi: 10.1253/circj.CJ-17-1131. Epub 2018 Feb 22.

Authors

Loukman Omarjee^{1

2

3

4}, Vincent Jaquinandi^{1

2}, Audrey Camarzana^{3

5}, Frederic Rouleau^{3

5}, Tin-Hinan Mezdad^{3

5}, Thierry Le Tourneau^{6

7}, Guillaume Mahe^{1

2}, Cristina Belizna^{3

8}

Affiliations

¹ Vascular Medicine Department, Rennes University.
² Rennes University Hospital Center, Rennes University.
³ MITOVASC Institute, Angers University.
⁴ Department of Vascular Medicine, Redon Hospital Center.
⁵ Department of Cardiology, Angers University Hospital Center.
⁶ Department of Cardiovascular Investigations, Nantes University Hospital Center.
⁷ Thorax Institute, Nantes University.
⁸ Vascular and Coagulation Center, Angers University Hospital Center.

PMID: 29467357
DOI: 10.1253/circj.CJ-17-1131

No abstract available

Publication types

Case Reports

MeSH terms

Anticoagulants / pharmacology
Anticoagulants / therapeutic use*
Antiphospholipid Syndrome / complications
Antiphospholipid Syndrome / drug therapy*
Antirheumatic Agents / therapeutic use*
Drug Therapy, Combination
Endocarditis / complications
Endocarditis / drug therapy*
Follow-Up Studies
Humans
Hydroxychloroquine / therapeutic use*
Lupus Erythematosus, Systemic / complications
Lupus Erythematosus, Systemic / drug therapy*
Male
Treatment Outcome
Vitamin K / antagonists & inhibitors
Warfarin / pharmacology
Warfarin / therapeutic use*
Young Adult

Substances

Anticoagulants
Antirheumatic Agents
Vitamin K
Hydroxychloroquine
Warfarin